Phase 3 trial results showed the once-weekly Cagrilintide monotherapy injection helped patients reduce their weight by 11.8% on average after 68 weeks.
The report says officials plan to include the claim in a presentation next week to a key vaccine panel that advises the CDC on shot access and coverage.